公司简介
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...
关联新闻
- Amgen's experimental Sjogren's drug meets late-stage trial goal
Amgen said on Wednesday its experimental drug showed sustained reduction in disease activity in a late-stage study of patients with Sjogren's disease, an autoimmune condition.
- Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
A drug from Amgen could give patients with a notoriously aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca. Full results from a late-stage...
- These Consumer Stocks Are Getting a Lift as Investors Rotate Out of Tech
Some beaten-down consumer names are getting a boost as investors pull back from tech stocks.
- Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets
Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs.
- Amgen's autoimmune drug succeeds in late-stage trial
Amgen said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body's moisture-producing glands met the main goal of reducing disease activity in a late-stage trial.
- Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
- Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead
CNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market. He highlighted aerospace, fintech, health care and energy ...
- Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday
U.S.-listed shares of Novartis are slumping Tuesday morning following disappointing clinical trial results from the Swiss drugmaker.